Suchergebnisse - (Subject:"Immunologic Factors")

1

Antibody response following SARS-CoV-2 infection and implications for immunity : final update of a rapid, living review

Erschienen: [Rockville, Md.], Agency for Healthcare Research and Quality, July 2022

Rapid evidence product - no. 22(23)-EHC037

Version 3.0.

von Holmer, H.

2

Antibody response following SARS-CoV-2 infection and implications for immunity : a rapid living review

Erschienen: [Rockville, Md.], Agency for Healthcare Research and Quality, March 2021

Rapid evidence product - no. 21-EHC016

von Mackey, K.

3

Immunomodulatory biomaterials : regulating the immune response with biomaterials to affect clinical outcome

Erschienen: Duxford, Woodhead Publishing, 2021

Woodhead Publishing series in biomaterials

von Badylak, S. | Elisseeff, J.

4

Clinical review report : indication : indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisableDupilumab (Dupixent) (Sanofi genzyme, a division of Sanofi-Aventis Canada Inc.)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, June 2020

CADTH common drug review

Version: Final.

5

Biomaterials and immune response : complications, mechanisms and immunomodulation

Erschienen: Boca Raton, CRC Press, Taylor & Francis Group,, [2019]

Devices, circuits, and systems

von Vrana, N.

6

Second-line therapy for patients with relapsing-remitting multiple sclerosis : a review of guidelines

Erschienen: Ottawa (ON), CADTH, September 26, 2019

CADTH rapid response report: summary with critical appraisal

von Li, K. | Picheca, L.

7

Biologics versus immunomodulators or antibiotics for the management of fistulizing Crohn's disease : a review of comparative clinical effectiveness and cost-effectiveness

Erschienen: Ottawa (ON), CADTH, March 29, 2019

CADTH rapid response report: summary with critical appraisal

Version 1.0.

von Young, C. | Campbell, K.

8

Antibody therapy : substitution – immunomodulation – monoclonal immunotherapy

Erschienen: Cham, Switzerland, Springer, [2018]

SpringerLink, Bücher

von Imbach, P.

9

Role of complement receptors C5aR and C5L2 in bone metabolism

Erschienen: Dissertation, Universität Ulm, 2019

von Matthes, R.

10

CADTH Canadian Drug Expert Committee recommendation : indication : management of adult patients with early primary progressive multiple sclerosis (PPMS) as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activityOcrelizumab (Ocrevus-Hoffmann-La Roche Limited)

Erschienen: Ottawa (ON), CADTH, April 30, 2018

CADTH common drug review

Version: 1.0.

Filter & Sortierung